Clinical trial
FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients…
NCT00079443 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00079443 |
|---|---|
| Title | FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study of Single Agent Depsipeptide (NSC 630176) Followed by a Phase I Study of Rituximab/Fludarabine Combination With an Escalating Dose of Depsipeptide in Relapsed or Refractory Low Grade B Cell Lymphomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma |
| Intervention type | Biological, Drug, Other |
| Interventions | romidepsin, rituximab, fludarabine phosphate, laboratory biomarker analysis |
| Enrollment | 60 |
| Start date | Jan 1, 2004 |
| Primary completion | Sep 1, 2005 |
| First posted | Mar 10, 2004 |
| Last update posted | Jul 1, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: